Gogo Inc. has amended and extended its Term Loan B, pushing the maturity date to October 2030 and reducing debt by $75 million through 2027, including an immediate $25 million paydown. This move aims to improve Gogo's financial position and provide more time to execute its strategy of expanding high-speed broadband services in business and military aviation markets. The extension offers greater flexibility for debt reduction and balance sheet strengthening, reflecting lender confidence in Gogo's future. The company plans further steps to deleverage and transform its business.
Gogo Inc.'s loan amendment and extension is the subject here, providing context for readers. For those following Industrials, of 135 US stocks tradable on Pluang, 75 rose and 54 fell today. Notable movers include FPS at USD 19.60 (+7.63%), VRT at USD 188.77 (+6.81%), and TE at USD 2.42 (+6.14%) as of Nov 06, 2026 20:12 WIB.
BriaCell Therapeutics and its subsidiary BriaPro presented positive preclinical data at the SITC 2026 Annual Meeting, highlighting their immunotherapy platforms Bria-OTS+ and BP-80. Bria-OTS+ showed broad immune activation and sustained cancer cell k...
IMUNON, Inc. presented new data from its Phase 2 OVATION 2 trial showing that IMNN-001, combined with chemotherapy, significantly enhances anti-tumor T-cell immune responses in advanced ovarian cancer patients. This immune activation correlates with ...
Canary Capital has launched the Canary Staked INJ ETF (INJC) on Nasdaq, providing investors exposure to INJ, the native token of the Injective blockchain. The ETF not only tracks INJ's price but also earns staking rewards from the network's proof-of-...
The Ozempic market, valued at $30.04 billion in 2026, is projected to grow to $113.95 billion by 2032, with a CAGR of 24.89%. This growth is fueled by increasing demand for diabetes and metabolic health treatments, wider adoption of GLP-1 therapies, ...
Minerva Neurosciences announced its third quarter 2026 financial results and business updates, highlighting progress in its Phase 3 trial of roluperidone, a drug targeting negative symptoms of schizophrenia. The ongoing C19 study aims to confirm prio...
